Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 7/20 | 0.43 |
| ▸ | AURKA | O14965 | 7/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | LYN | P07948 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | MARK3 | P27448 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | BLK | P51451 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | STK3 | Q13188 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.41 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744643 | 0.98 | AURKB (0.45) | AURKBAURKANTRK1LCKFYN | |
| SCHEMBL744950 | 0.92 | AURKA (0.40) | AURKBAURKANTRK1LCKFYN | |
| SCHEMBL15221937 | 0.91 | AURKB (0.46) | AURKBAURKANTRK1LCKFYN | |
| SCHEMBL275501 | 0.89 | AURKB (0.44) | AURKBAURKANTRK1LCKFYN | |
| SCHEMBL15221915 | 0.88 | FGFR1 (0.47) | AURKBAURKANTRK1LCKFYN | |
| SCHEMBL744854 | 0.87 | FLT3 (0.38) | AURKBAURKANTRK1LCKFYN | |
| SCHEMBL15221976 | 0.86 | AURKB (0.46) | AURKBAURKANTRK1LCKFYN | |
| Bromide SCHEMBL741865 | 0.86 | FLT3 (0.38) | AURKBAURKANTRK1LCKFYN | |
| Hydrochloric Acid SCHEMBL744245 | 0.86 | FLT3 (0.38) | AURKBAURKANTRK1LCKFYN | |
| SCHEMBL743360 | 0.86 | FGFR1 (0.38) | AURKBAURKANTRK1LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | claimed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | claimed |
| EP-2203060-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | Bayer Healthcare, LLC (US) | 2010-07-07 | — | — | EP | claimed |
| WO-2009042543-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2009-04-02 | — | — | WO | claimed |
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
| EP-2203060-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | Bayer Healthcare, LLC (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009042543-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | AURKB 4/4885AURKA 2/4885NTRK1 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.